8 recruiting, 6 active not recruiting, 1 suspended, 1 unknown. 9 Phase 1, 8 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Active not recruiting 5, Recruiting 2, Suspended 1, Unknown 1 |
| Phase 2 | 8 | Recruiting 5, Active not recruiting 2, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Chimeric Antigen Receptor T-Cell Therapy: new trials by email Literature Review of Chimeric Antigen Receptor T-Cell Therapy trials Research Report on Chimeric Antigen Receptor T-Cell Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography - Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2025-06-17 | 2026-10-22 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-11-08 | 2026-03-31 |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | City of Hope Medical Center | 9 | 2023-07-20 | 2026-02-04 |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy - Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Recruiting | Lazaros Lekakis | 22 | 2022-12-14 | 2025-12-31 |
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration - Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | Northwestern University | 24 | 2022-03-21 | 2024-10-16 |
| Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | University of California, Davis | 36 | 2021-09-17 | 2026-07-17 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Chimeric Antigen Receptor T-Cell Therapy - Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2018-11-27 | 2026-08-12 |
| CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide - B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric | Phase 1 / Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 18 | 2018-05-14 | 2023-02-24 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 33 | 2017-10-20 | 2026-06-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 56 | 2017-09-01 | 2025-11-18 |
Lymphoma, Large B-Cell, Diffuse (8) · Burkitt Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Neoplasm, Residual (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Glioblastoma (1) · Hematologic Diseases (1) · Leukemia, Lymphoid (1)
City of Hope Medical Center (4) · Stanford University (2) · University of California, Davis (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Lazaros Lekakis (1) · Mayo Clinic (1) · Northwestern University (1) · University of Washington (1)
United States (15) · Russia (1)
Amandeep Salhotra (1) · Behnam Badie (1) · Claire Tiger, MD, PhD (1) · Crystal Mackall (1) · Jana L Portnow (1) · Joseph M Tuscano, MD (1) · Lazaros Lekakis, MD (1) · Lori Muffly, MD, MS (1) · Mazyar Shadman (1) · Mehrdad Abedi (1) · Mengyang Di, MD, PhD (1) · Michael Jain, MD, PhD (1) · Reem Karmali, MD (1) · Sarah Larson, MD (1) · Savita V Dandapani (1)
PMID 34515338, PMID 32929049, PMID 34312556, PMID 34889384, PMID 34893603, PMID 38968138
P30CA033572 (3), P30CA093373 (2), P30CA060553 (1)